Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VEGFA siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravitreal, Ophthalmic, Intratumoral, Intravenous, Intraperitoneal, Subcutaneous
01
Overview
VEGFA siRNA is a small interfering RNA (siRNA) designed to silence the expression of Vascular Endothelial Growth Factor A (VEGFA). It functions through the RNA interference (RNAi) pathway, where the siRNA sequence guides the RNA-induced silencing complex (RISC) to bind and cleave VEGFA messenger RNA (mRNA), thereby preventing the translation of the VEGFA protein. VEGFA is a critical signaling protein that promotes angiogenesis (the formation of new blood vessels) and increases vascular permeability. By inhibiting VEGFA production, this therapeutic approach aims to treat conditions characterized by pathological neovascularization, such as age-related macular degeneration, diabetic retinopathy, corneal neovascularization, and various solid tumors. Because naked siRNA is susceptible to degradation and has poor cellular uptake, it is typically formulated with delivery vehicles such as lipid nanoparticles (LNPs), exosomes, or targeted peptide carriers.
- Other names
- anti-VEGFA siRNAVEGF-A siRNAvascular endothelial growth factor A siRNAhVEGFA siRNA
02
Targets
VEGFA (Vascular endothelial growth factor A)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on VEGFA siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VEGFA siRNA.